Gilead Sciences, Inc.
COMBINATION OF A TLR7 MODULATING COMPOUND AND AN HIV VACCINE

Last updated:

Abstract:

The present disclosure describes methods, compositions, and kits related to the combination of a TLR7 modulating compound and an HIV vaccine. The combination can be used in a method of treating or preventing an HIV infection in a human.

Status:
Application
Type:

Utility

Filling date:

21 May 2020

Issue date:

14 Jul 2022